Healthcare & Pharma Awards 2022

52 GHP Healthcare & Pharma Awards 2022 Gendius is a health data and insights business focused on metabolic disease, which accounts for 33% of deaths around the world. The company develops algorithms that enable earlier identification of metabolic diseases and therefore earlier interventions which transform the outcomes for patients, save lives, and save money for global healthcare systems. Gendius’ mission is to build the world’s most comprehensive, rich metabolic data set to enable earlier identification and intervention of metabolic disease. The system streamlines care for healthcare teams and personalises this for each patient, with its data collected directly from electronic health records, registries, and the patient via its intellin remote management platform. The company has also developed unique pre-screening algorithms that predict an individual’s risk of developing complications. The team at Gendius are experts in metabolic longitudinal data and methodologies to extract insights and predict outcomes. This inhouse expertise means that the company can lead the way and set the agenda when it comes to individual patient-centric risk prediction for metabolic disease. Its dedicated data science and algorithm team, led by Dr Rose Sisk, Phd Health Informatics, Data Scientist; and Dr Camilla SammutPowell, Phd Statistics, Senior Data Analysist, has been developing complex models that are able to predict reduced eGFR (estimated glomerular filtration) in people with diabetes and/or hypertension. These algorithms enable more efficient and effective use of current screening programmes. Gendius’ eGFR model, which identifies patients with reduced eGFR, was validated against the three-year observational DISCOVER data study (covering 38 countries in six regions globally) and iCaReMe registry (covering 21 countries in six regions globally). Gendius has also partnered with over 60 primary care practices to analyse real-world data from thousands of people with diabetes to validate and improve its CKD risk prediction models. Additional model validation is underway, too, using electronic health record data in over 100,000 people in Taiwan, as well as Salford in the UK through the Salford Integrated Record (SIR). Gendius’ current recommendations are for all 340m people with diabetes to be screened for chronic kidney disease (CKD) every year, with the evidence showing only 30% will test positive. Its algorithms have disrupted the current ‘screen all’ approach, reducing the number of patients needing to go for unnecessary and costly blood tests by over 33%. Its algorithms can be used to increase the accessibility of screening whilst significantly reducing the costs. This allows patients at risk of complications to be identified sooner, enabling earlier healthcare intervention, earlier use of lifesaving medicine, improved patient management, and reduced costs. In addition to disrupting this ‘screen all’ approach in diabetes, Gendius is developing algorithms to predict the risk of CKD in hypertension and heart failure in diabetes. These algorithms will be used to power the intellin platform, which is currently used to power AstraZeneca’s Health Gate patient support app, allowing users in the GCC region to track and manage their diabetes on a daily basis. Gendius prides itself on global demand for and uptake of its risk prediction technology. It has a Global Master Service Agreement (MSA) in place with AstraZeneca where it has validated its CKD pre-screening algorithm in their global data sets, and it is in commercial discussions about a licencing deal. Also, Gendius is working with B Grimm, a leading healthcare provider in Thailand to help them set up new diabetes clinics with a focus on the prevention of complications and screening. Furthermore, the company is in discussions with another large pharmaceutical company regarding licencing and validating its algorithms in their data along with Health Information Organisation in the US. Now, Gendius is getting close to the stage of being able to publish the results of its pre-screening model validations, and it has a number of publications coming towards the end of 2022 and early 2023. The publication of these results will bring the company closer to using its pre-screening methods with real-world patients. The hope is that its CKD models in particular could be used to better target CKD screening within type-2 patients populations, especially in low- and middle-income countries where screening resources are more limited. Company: Gendius Ltd Contact: Rory Cameron, CEO Email: [email protected] Website: Most Innovative HealthTech Company 2022 - UK Jul22163